Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEB-01 in paediatric locally resectable abdominal tumours
2024-520054-38-00Phase 2Suspended
- Sponsor
- Cebiotex
- Start
- Apr 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CEB-01 in desmoplastic small round cell tumor (DSRCT), Wilms' tumor, malignant rhabdoid tumor (MRT) and 5 more, sponsored by Cebiotex. Primary endpoint: Adverse events (serious and non-serious). Started Apr 2025; status: suspended.
02
Drugs
CEB-01
03
Conditions
desmoplastic small round cell tumor (DSRCT)Wilms' tumormalignant rhabdoid tumor (MRT)neuroblastomasoft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2024-520054-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520054-38-00.